Trump's SEC leader shifts power from investors to boardrooms
New policies from the top U.S. securities regulator hand corporate boards more power over investors in ways that could ...
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 ...